

Title (en)  
CORRELATION BETWEEN THE FUCOSE CONTENT / GALACTOSE CONTENT RATIO OF ANTI-RHESUS-D AND ANTI-HLA-DR ANTIBODIES AND THE ADCC ACTIVITY

Title (de)  
KORRELATION ZWISCHEN DEM FUCOSEGEHALT/ GALACTOSEGEHALT-VERHÄLTNIS VON ANTI-RHESUS-D- UND ANTI-HLA-DR-ANTIKÖRPERN UND DER ADCC-AKTIVITÄT

Title (fr)  
CORRELATION DU RATIO TAUX DE FUCOSE / TAUX DE GALACTOSE D'ANTICORPS ANTI RHESUS D ET ANTI HLA-DR AVEC L'ACTIVITE ADCC

Publication  
**EP 1675873 A1 20060705 (FR)**

Application  
**EP 04805250 A 20041020**

Priority  
• FR 2004002686 W 20041020  
• FR 0312229 A 20031020

Abstract (en)  
[origin: US2007015239A1] The present invention relates to monoclonal antibodies with high ADCC activity, characterised in having glycanic structures with a ratio (fucose content/galactose content) of 0.6 or less on the glycosylation site thereof in the Fc region. The invention also relates to pharmaceutical compositions, containing said monoclonal antibodies with high effector activity.

IPC 1-7  
**C07K 16/34**; C07K 16/00; A61P 31/00; A61P 35/00; A61P 37/06; C12N 5/12; A61K 39/395; C07K 16/28

IPC 8 full level  
**A61P 31/00** (2006.01); **A61P 35/00** (2006.01); **C07K 16/00** (2006.01); **C07K 16/28** (2006.01); **C07K 16/34** (2006.01)

CPC (source: EP US)  
**A61P 7/04** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/00** (2017.12 - EP); **A61P 31/06** (2017.12 - EP); **A61P 31/12** (2017.12 - EP); **A61P 33/00** (2017.12 - EP); **A61P 33/12** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **C07K 16/00** (2013.01 - EP US); **C07K 16/2833** (2013.01 - EP US); **C07K 16/34** (2013.01 - EP US); **A61K 2039/505** (2013.01 - EP US); **C07K 2317/21** (2013.01 - EP US); **C07K 2317/24** (2013.01 - EP US); **C07K 2317/41** (2013.01 - EP US); **C07K 2317/732** (2013.01 - EP US)

Citation (search report)  
See references of WO 2005040221A1

Citation (examination)  
• MORI KATSUHIRO ET AL: "Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies.", CYTOTECHNOLOGY DEC 2007 LNKD- PUBMED:19003000, vol. 55, no. 2-3, December 2007 (2007-12-01), pages 109 - 114, XP019550382, ISSN: 0920-9069  
• B. M. KUMPEL: "Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers", VOX SANGUINIS, vol. 93, no. 2, 1 August 2007 (2007-08-01), pages 99 - 111, XP055002584, ISSN: 0042-9007, DOI: 10.1111/j.1423-0410.2007.00945.x

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**US 2007015239 A1 20070118**; AU 2004283924 A1 20050506; AU 2004283924 B2 20101202; BR PI0415565 A 20070102; CA 2542881 A1 20050506; EP 1675873 A1 20060705; FR 2861080 A1 20050422; FR 2861080 B1 20060217; IL 174896 A0 20060820; JP 2007533299 A 20071122; WO 2005040221 A1 20050506

DOCDB simple family (application)  
**US 57533306 A 20060412**; AU 2004283924 A 20041020; BR PI0415565 A 20041020; CA 2542881 A 20041020; EP 04805250 A 20041020; FR 0312229 A 20031020; FR 2004002686 W 20041020; IL 17489606 A 20060410; JP 2006534807 A 20041020